New Mechanisms of Signal Transduction Inhibitor Action

The explosion of signal transduction research over the last 10 years has provided a unique insight into the complexity of these intricate pathways. Whereas intermediates of multiple signaling pathways have been identified, understanding their function and, in particular, the interactions between them has become a daunting task. The increasing evidence that many of these pathways can cross-talk with each other via signal transactivation inevitably raises the question of how cells determine specificity in signaling. Despite the mind-numbing complexity of these pathways, progress has been made in developing highly specific and potent signal transduction inhibitors (STIs). STIs show promise in the treatment of cancer in preclinical studies and are currently in a number of clinical trials. Whereas many of these agents were “rationally designed,” we barely understand their mechanisms of action. This review will highlight how recent studies using these STIs have elucidated novel mechanisms of STI action that may be used in the development of new therapeutic strategies for the treatment of cancer.

[1]  D. Yee,et al.  Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. , 2002, Cancer research.

[2]  Venter Jc.  Genomic impact on pharmaceutical development. , 2000 .

[3]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[4]  M. Brattain,et al.  Activation of the TGFα autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells , 2002, Oncogene.

[5]  S. Soltoff.  Related Adhesion Focal Tyrosine Kinase and the Epidermal Growth Factor Receptor Mediate the Stimulation of Mitogen-activated Protein Kinase by the G-protein-coupled P2Y2 Receptor , 1998, The Journal of Biological Chemistry.

[6]  D. Coppola,et al.  A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[7]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[8]  R. Baserga,et al.  Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. , 1996, Experimental cell research.

[9]  A. Ullrich,et al.  Distinct Calcium-dependent Pathways of Epidermal Growth Factor Receptor Transactivation and PYK2 Tyrosine Phosphorylation in PC12 Cells* , 1999, The Journal of Biological Chemistry.

[10]  P. Kelly,et al.  The Prolactin/Growth Hormone Receptor Family: Structure/Function Relationships , 2004, Journal of Mammary Gland Biology and Neoplasia.

[11]  H. Huynh,et al.  Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. , 1997, Biochemical and biophysical research communications.

[12]  C. Dive,et al.  Extracellular Matrix Regulates Apoptosis in Mammary Epithelium through a Control on Insulin Signaling , 1999, The Journal of cell biology.

[13]  C. Osborne,et al.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. , 1989, Cancer research.

[14]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[15]  K. Korach,et al.  Requirement of Estrogen Receptor-α in Insulin-like Growth Factor-1 (IGF-1)-induced Uterine Responses and in Vivo Evidence for IGF-1/Estrogen Receptor Cross-talk* , 2002, The Journal of Biological Chemistry.

[16]  A. Arkin.  Synthetic cell biology. , 2001, Current opinion in biotechnology.

[17]  C. Streuli,et al.  Extracellular Matrix Selectively Modulates the Response of Mammary Epithelial Cells to Different Soluble Signaling Ligands* , 1999, The Journal of Biological Chemistry.

[18]  D. Leroith.  Insulin-like growth factor receptors and binding proteins. , 1996, Bailliere's clinical endocrinology and metabolism.

[19]  N. Rosen,et al.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.

[20]  L. Shaw.  Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the α6β4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion , 2001, Molecular and Cellular Biology.

[21]  L. Norton,et al.  Focus on breast cancer. , 2002, Cancer cell.

[22]  A. Ullrich,et al.  Cell‐type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor , 1999, The EMBO journal.

[23]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[24]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[25]  J. Ting,et al.  MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis* , 2000, The Journal of Biological Chemistry.

[26]  A. Ullrich,et al.  Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission , 2001, Oncogene.

[27]  C. Rondinone,et al.  Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. , 2001, Diabetes.

[28]  C. Osborne,et al.  Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. , 2001, Cancer research.

[29]  Kohjiro Ueki,et al.  Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.

[30]  A. Ullrich,et al.  Signal characteristics of G protein‐transactivated EGF receptor , 1997, The EMBO journal.

[31]  Y. Taketani,et al.  Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer* , 2000, The Journal of Biological Chemistry.

[32]  R. G. Anderson,et al.  Spatial organization of EGF receptor transmodulation by PDGF. , 1999, Biochemical and biophysical research communications.

[33]  A. Ullrich,et al.  Receptor tyrosine kinase signalling as a target for cancer intervention strategies. , 2001, Endocrine-related cancer.

[34]  E. Peralta,et al.  The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity , 1997, The EMBO journal.

[35]  L. Hennighausen,et al.  Regulation of Mammary Differentiation by Extracellular Matrix Involves Protein-tyrosine Phosphatases* , 1998, The Journal of Biological Chemistry.

[36]  S. Korsmeyer,et al.  Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[37]  W. Sly,et al.  Insulin-like growth factor receptor expression and function in human breast cancer. , 1990, Cancer research.

[38]  D. Clemmons,et al.  Blocking ligand occupancy of the αVβ3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells , 1998 .

[39]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[40]  Adrian V. Lee,et al.  Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3′-Kinase Inhibition , 2000, Molecular and Cellular Biology.

[41]  Adrian V. Lee,et al.  Inability of Overexpressed des(1-3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules. , 2001, Endocrinology.

[42]  Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials , 2001 .

[43]  J. Goldberg,et al.  Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. , 1999, Diabetes.

[44]  N. Rosen,et al.  Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.

[45]  Andre Levchenko,et al.  Computational cell biology in the post-genomic era , 2004, Molecular Biology Reports.

[46]  N. Hynes,et al.  Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. , 2001, Cancer research.

[47]  M. Crescenzi,et al.  α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines , 1997 .

[48]  D. Clemmons,et al.  Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Ratan,et al.  The Epidermal Growth Factor Receptor Associates with and Recruits Phosphatidylinositol 3-Kinase to the Platelet-derived Growth Factor β Receptor* , 1998, The Journal of Biological Chemistry.

[50]  D. Yee,et al.  The IGF system and breast cancer. , 2001 .

[51]  A. Citri,et al.  Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy , 2002, The EMBO journal.

[52]  D. Yee,et al.  Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. , 1997, The Journal of endocrinology.

[53]  J. Olefsky,et al.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.

[54]  J. Olefsky,et al.  Persistent activation of phosphatidylinositol 3-kinase causes insulin resistance due to accelerated insulin-induced insulin receptor substrate-1 degradation in 3T3-L1 adipocytes. , 2000, Endocrinology.

[55]  E. Ruoslahti,et al.  Association of insulin receptor substrate-1 with integrins. , 1994, Science.

[56]  E. Ruoslahti,et al.  αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF , 1997 .

[57]  R. Roth,et al.  Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation by an Akt/Phosphatidylinositol 3-Kinase Pathway* , 1999, The Journal of Biological Chemistry.

[58]  J. Sedivy,et al.  Regulation of cyclin-Cdk activity in mammalian cells , 2002, Cellular and Molecular Life Sciences CMLS.

[59]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[60]  Martin A. Schwartz,et al.  Networks and crosstalk: integrin signalling spreads , 2002, Nature Cell Biology.

[61]  R L Juliano,et al.  Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. , 2002, Annual review of pharmacology and toxicology.

[62]  M. Callery,et al.  Ubiquitin proteasome inhibition and cancer therapy. , 2002, Surgery.

[63]  M. Maa,et al.  c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.